Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T13:23:22.184Z Has data issue: false hasContentIssue false

79 - Lidocaine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Xylocaine, Akten, Alphacaine, Anestacon, Dentipatch, Glydo, Lidocaton, Zingo

Generic?

• Yes

Class

• Antiarrhythmic

Commonly Prescribed for

(FDA approved in bold)

Regional anesthesia

Ventricular arrhythmias

• Post-herpetic neuralgia (patch only)

• Intractable headache

• Trigeminal autonomic cephalalgia

• Symptomatic myotonia

• Pain after spinal cord injury

• Tinnitus

How the Drug Works

• Class 1b antiarrhythmic agent. It blocks fast voltage-gated sodium channels on neuronal cell membrane, resulting in inhibition of the ionic flow required for initiation and conduction of action potentials and thus creating the anesthetic effect

• It also reduces the effective refractory period in Purkinje fibers in the heart and raises the depolarization threshold of the ventricle during diastole

How Long Until It Works

• Anesthetic and antiarrhythmic effects will occur within minutes

• May take more time (days or weeks) to see relief and determine the most effective dose in myotonia or pain disorders

If It Works

• Continue to use with appropriate monitoring

If It Doesn't Work

• Check serum levels and if not effective change to an alternative agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Bupivacaine for long-acting local anesthesia

Tests

• Obtain ECG at baseline and for any new symptoms. Check a serum lidocaine level to guide therapy (1.5–6mcg/mL) and for any AEs

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Drug effect blocking sodium channels

Notable AEs

• Dizziness, bradycardia, paresthesias, perioral numbness, hypo or hypertension, and tremor. Convulsions, visual disturbances (including hallucinations), depression, euphoria, agitation, or paranoid ideation

Life-Threatening or Dangerous AEs

• New or worsening cardiac arrhythmias

• Methemoglobinemia

Weight Gain

• Unusual

Sedation

• Unusual

What to Do About AEs

• Check serum level and ECG. For serious AEs, discontinue drug

Best Augmenting Agents to Reduce AEs

• Most AEs cannot be reduced by an augmenting agent

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 295 - 297
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Lidocaine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.080
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Lidocaine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.080
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Lidocaine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.080
Available formats
×